References
- Kumar N, Zhang NJ, Cherepanov D, et al. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022;17(1):278. Jul 19 doi:10.1186/s13023-022-02414-6.
- Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. Jul 2 doi:10.1161/CIRCULATIONAHA.118.038169.
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. Sep 13 doi:10.1056/NEJMoa1805689.
- Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. Jul 5 doi:10.1056/NEJMoa1716153.
- Elliott P, Drachman BM, Gottlieb SS, et al. Long-Term survival With tafamidis in patients With transthyretin amyloid cardiomyopathy. Circulation Heart Failure. 2022;15(1):e008193. Jan
- Rettl R, Mann C, Duca F, et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23(6):767–780. Jun 1 doi:10.1093/ehjci/jeab226.
- Chamling B, Bietenbeck M, Korthals D, et al. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clin Res Cardiol. 2023;112(3):353–362. May
- Fischer K, Linder OL, Erne SA, et al. Reproducibility and its confounders of CMR feature tracking myocardial strain analysis in patients with suspected myocarditis. Eur Radiol. 2022;32(5):3436–3446. May doi:10.1007/s00330-021-08416-5.
- Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume With patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189–199. Jan doi:10.1016/j.jcmg.2020.07.043.
- Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–1579. Oct 20 doi:10.1161/CIRCULATIONAHA.115.016567.